VISCHER advised Polyneuron in its Series A Financing extension to CHF 36.5m
Polyneuron Pharmaceuticals, a clinical stage developer of a new class of antigen-specific polymers for the treatment of patients affected by autoimmune diseases, extended its Series A by CHF 14m bringing the total to CHF 36.5m. HBM Healthcare Investments joins as additional investor to lead investor Sofinnova Partners and New Enterprise Associates.